Using dihydropyridine-release strategies to enhance load effects in engineered human bone constructs.
We report on the development of a novel biodegradable scaffold capable of enhancing mechanical signals for tissue-engineering applications. It has been shown that mechanotransduction enhances bone formation in vitro and in vivo; in tissue-engineering applications, this phenomenon is exploited through the use of mechanical bioreactors to generate bone tissue. The dihydropyridine agonist Bay K8644 (Bay) acts to increase the opening time of mechanosensitive voltage-operated calcium channels (VOCCs), specifi- cally L-type VOCCs, which are known to play a fundamental role in the early mediation of mechanotransduction. We have produced porous 3-dimensional, Bay-encapsulated biodegradable poly(L-lactide) acid scaffolds using a solvent-casting and salt-leaching technique. The effects of the released Bay on osteoid production and mineralization in human bone cell-seeded constructs following incubation in a perfusion-compression bioreactor in vitro was investigated using Western blotting techniques and a calcium assay protocol developed in our lab. Our newly developed scaffolds act by slowly releasing the calcium channel agonist Bay K8644 as observed using ultraviolet spectroscopy, maintaining the open state of mechanosensitive VOCCs responding to load, which augments the load signal at sites of strain across the scaffold. Our results demonstrate that, in the presence of physiological loading regimes in vitro, release of Bay enhances collagen I protein production and osteoid calcification more than non-Bay control constructs do. Osteopontin and alpha2delta1 VOCC subunit protein levels were also higher as a result of perfusion-compression conditioning. These results indicate that Bay-encapsulated scaffolds can be used in the presence of load to enhance the production of load-bearing engineered tissue.
Wood
Mairead A
MA
Institute of Science and Technology in Medicine, Keele University, Stoke-on-Trent, United Kingdom.
Yang
Ying
Y
Thomas
Peter B M
PB
Haj
Alicia J El
AJ
D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000737:chemistry / Q000494:pharmacology*; D001672:Biocompatible Materials / Q000737:chemistry; D019149:Bioreactors; D018786:Bone Substitutes / Q000737:chemistry; D001842:Bone and Bones / Q000166:cytology / Q000378:metabolism*; D002120:Calcium Channel Agonists / Q000737:chemistry / Q000494:pharmacology*; D015220:Calcium Channels; D002478:Cells, Cultured; D004343:Drug Implants / Q000737:chemistry; D016326:Extracellular Matrix Proteins / Q000096:biosynthesis; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D008422:Materials Testing / Q000379:methods; D040542:Mechanotransduction, Cellular / Q000187:drug effects*; D011091:Polyesters / Q000737:chemistry; D013314:Stress, Mechanical; D023822:Tissue Engineering / Q000379:methods; D016474:Weight-Bearing
D001672:Biocompatible Materials; D018786:Bone Substitutes; D002120:Calcium Channel Agonists; D015220:Calcium Channels; D004343:Drug Implants; D016326:Extracellular Matrix Proteins; D011091:Polyesters; C033616:poly(lactide); D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester